Investigational drug · Phase 3
RYZ101
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "RYZ101"
First trial start
2022
Mar 24, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RYZ101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Breast Cancer
- HER2-negative Breast Cancer
- ER+ Breast Cancer
- Advanced Breast Cancer
- Metastatic Breast Cancer With Bone Involvement
- Bone Metastases in Subjects With Advanced Breast Cancer
- ER-Positive HER2-Negative Breast Cancer
- Estrogen Receptor-positive Breast Cancer
- Hormone-sensitive Metastatic Breast Cancer
- Hormone-Sensitive Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "RYZ101" as an intervention, largest first.
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyPivotal-lookingActive, not recruiting
RayzeBio, Inc.Industry
NCT05477576 · 343 participants · Start Mar 24, 2022 · Primary completion Dec 2026
Drug: RYZ101; Everolimus and 3 more · For: GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease and 4 more
Sites: Phoenix, Arizona; Duarte, California; Irvine, California · 54 sites in all
RayzeBio, Inc.Industry
NCT06590857 · 64 participants (planned) · Start Jul 19, 2024 · Primary completion Oct 2028
Drug: RYZ101; Standard of Care Endocrine Therapy · For: Metastatic Breast Cancer; HER2-negative Breast Cancer; ER+ Breast Cancer and 7 more
Sites: Phoenix, Arizona; Irvine, California; San Diego, California · 32 sites in all
Joshua PalmerAcademic, hospital or other
NCT07150806 · 30 participants (planned) · Start Nov 12, 2025 · Primary completion Dec 31, 2026
Drug: Actinium Ac 225 DOTATATE RYZ101; L-lysine/L-arginine-containing Amino Acid · For: Recurrent Meningioma
Sites: Columbus, Ohio
- Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLCActive, not recruiting
RayzeBio, Inc.Industry
NCT05595460 · 21 participants · Start Oct 10, 2022 · Primary completion Jul 2027
Drug: RYZ101 Dose Level 1; RYZ101 Dose Level 2 and 5 more · For: SCLC,Extensive Stage
Sites: Los Angeles, California; San Francisco, California; Jacksonville, Florida · 13 sites in all
Jules Bordet InstituteAcademic, hospital or other
NCT06411301 · 0 participants · Start Oct 2024 · Primary completion Oct 2026
Drug: 225Ac-DOTATATE · For: Multiple Myeloma, Refractory; Multiple Myeloma in Relapse; Multiple Myeloma Progression
Sites: Brussels, Belgium
Newest research
PubMed records naming it or its code names, newest first.
- Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [225Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor-Expressing, Well-Differentiated GEP-NETs.
Sgouros G, Ulaner GA, He B, et al. · J Nucl Med 2026
- Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101.
Grewal US, Gbolahan OB, Takalkar AM, et al. · Future Oncol 2025
- RYZ101 (Ac-225 DOTATATE) Opportunity beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small-Cell Lung Cancer.
Han G, Hwang E, Lin F, et al. · Mol Cancer Ther 2023
Also in development for Metastatic Breast Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- LasofoxifeneAZU-101Phase 34 trials
Sermonix Pharmaceuticals Inc. · Metastatic Breast Cancer, Vulvo Vaginal Atrophy (VVA), Locally Advanced or Metastatic Breast Cancer
- TQB2930Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.